NCT05296681View on ClinicalTrials.gov

Microbiotic Product to Promote Microbiome Health and Improve Chemotherapy Delivery

PHASE2RecruitingINTERVENTIONAL
Enrollment

42

Participants

Timeline

Start Date

May 3, 2022

Primary Completion Date

July 1, 2025

Study Completion Date

July 1, 2025

Conditions
Metastatic Colon CarcinomaStage IV Colon Cancer AJCC v8Stage IVA Colon Cancer AJCC v8Stage IVB Colon Cancer AJCC v8Stage IVC Colon Cancer AJCC v8
Interventions
DRUG

NBT-NM108

Patients receive irinotecan-based chemotherapy per standard of care.

Trial Locations (10)

08690

RECRUITING

Robert Wood Johnson University Hospital, Hamilton, Hamilton

08701

RECRUITING

Monmouth Medical Center, Lakewood

RECRUITING

RWJBarnabas Health - Monmouth Medical Center Southern Campus, Lakewood

07039

RECRUITING

Cooperman Barnabas Medical Center, Livingston

08901

RECRUITING

Robert Wood Johnson University Hospital, New Brunswick

08903

RECRUITING

Rutgers Cancer Institute of New Jersey, New Brunswick

07103

RECRUITING

The Cancer Center, Newark

07112

RECRUITING

Newark Beth Israel Medical Center, Newark

08876

RECRUITING

Robert Wood Johnson University Hospital, Somerset, Somerville

08753

RECRUITING

Community Medical Center, Toms River

All Listed Sponsors
lead

Howard S. Hochster, MD

OTHER